Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Hepatocellular carcinoma (HCC) is on the rise worldwide, and its incidence in diabetic patients is two to three times that of non-diabetics. Current therapeutic options fail to provide considerable survival benefits to patients with HCC. There is a strong possibility that the FDA-approved antidiabet...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Amir Mohamed Abdelhamid, Sameh Saber, Mahmoud E. Youssef, Ahmed Gaafar Ahmed Gaafar, Hanan Eissa, Marwa A. Abd-Eldayem, Mohammed Alqarni, Gaber El-Saber Batiha, Ahmad J. Obaidullah, Mohamed Awad Shahien, Eman El-Ahwany, Noha A. Amin, Mohamed Ali Etman, Mohamed M.Y. Kaddah, Eslam E. Abd El-Fattah
Format: article
Langue:EN
Publié: Elsevier 2022
Sujets:
Hepatocellular carcinoma
Emagliflozin/metformin
Autophagy
Apoptosis
Angiogenesis
Metastasis
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8

Documents similaires